Tarsus Pharmaceuticals, Inc. TARS Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year five).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year five)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported finite-lived intangible assets - expected amortization expense (year five) of $2.56M in Q4 2025.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year five)?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year five) has grown at a 17.1% compound annual growth rate (CAGR), from $1.87M to $2.56M.
- What does finite-lived intangible assets - expected amortization expense (year five) mean?
- The projected amortization expense for intangible assets with finite useful lives specifically for the fifth year following the current reporting period. This helps investors model long-term non-cash expenses and understand the future impact of asset depreciation on net income.